Cu Medical Systems

CU Medical Systems develops, manufactures and sells automated external defibrillators (AEDs) and other emergency medical devices, and is recognized as Korea's first AED maker with a domestic market share above 50%.

The company offers a full product line from public-access AEDs to hospital-grade defibrillators, holding US FDA, European CE, and Japanese JFDA certifications that support exports to more than 80 countries.

Japan is considered an especially demanding market for quality standards, and CU Medical is the only Korean company exporting AEDs there, having supplied the market for more than a decade.

Its Japan subsidiary has expanded participation in tenders and public procurement, and recently signed a roughly 10,000-unit AED contract with Japan's Ramico, extending four consecutive years of order growth.

The German subsidiary supplies AEDs to major UK supermarket chains, focusing on the public-access segment in Europe.

In November 2025 the company agreed to acquire a 33.88% stake (about 22 billion won) in Vistos, a maker of patient-monitoring and vital-signs devices, completing the change of largest shareholder in January 2026.

Vistos focuses on fetal and neonatal devices and patient monitors, generating most of its revenue from exports across roughly 120 countries, and the deal allows CU Medical to add Class 1 and 2 lower-risk devices to its Class 3 (AED)-centered lineup, building a portfolio spanning emergency, diagnostic and monitoring devices.

The two companies are integrating research labs and manufacturing/quality-control systems to reduce duplicate investment and strengthen cost competitiveness.

Consolidated revenue in 2025 reached 48.2 billion won, up from 40.6 billion won in 2024, with operating profit of 10.8 billion won and a 22.4% operating margin.

After posting a 23.0% operating margin and 9.1 billion won in owners' net profit in 2022, the company swung to net losses in both 2023 (11.8% margin, 8.2 billion won loss) and 2024 (19.2% margin, 3.2 billion won loss) before returning to a small profit of 819 million won in 2025.

Operating cash flow remained positive throughout this period—3.1 billion won in 2022, 8.3 billion won in 2023, 14.1 billion won in 2024 and 9.7 billion won in 2025—suggesting the reported net losses in 2023-2024 were heavily influenced by non-cash items rather than cash operations.

On a quarterly basis, revenue of 12.4 billion won, operating profit of 3.2 billion won and net income of 0.6 billion won in the second quarter of 2025 were followed by a third quarter with lower revenue of 11.3 billion won but higher net income of 1.9 billion won.

The fourth quarter posted the year's highest operating profit of 4.1 billion won on revenue of 15.7 billion won, yet owners' net income was a loss of 2.4 billion won, a divergence between operating and net results.

In 2026, first-quarter revenue of 15.3 billion won, operating profit of 2.5 billion won and net income of 3.0 billion won were followed by second-quarter records of 20.2 billion won in revenue and 6.0 billion won in operating profit (roughly a 29.6% margin), with net income surging to 7.1 billion won.

As a result, owners' net income summed over the trailing four quarters (Q3 2025 through Q2 2026) reached 9.7 billion won, far exceeding the full-year 2025 figure of 819 million won, indicating an acceleration in profit improvement through the first half of 2026.

The debt ratio rose from 49.5% in 2022 to 58.0% in 2023 and 74.6% in 2024 before easing to 67.0% in 2025, showing the financial structure has alternated between strain and relief as the business expanded.

The AED industry is generally classified as a demand-growth sector supported by an aging population, rising cardiovascular disease rates, and policy tailwinds such as mandatory installation requirements and expanded penalty provisions for public facilities.

In Korea, CU Medical is regarded as the pioneering AED manufacturer with a market share above 50%.

Entry into overseas markets hinges on country-specific certification, and Japan in particular is known for extremely strict quality standards; CU Medical is the only Korean company exporting AEDs there, which functions both as a barrier to entry and a competitive advantage.

In Europe, regulatory discussions are moving toward requiring remote management of installed AEDs, increasing demand for systems that can remotely track battery and pad status along with inspection history.

Competitively, domestic and international emergency and precision medical device makers compete on the basis of country certifications and distribution networks, and CU Medical differentiates itself through certification and sales networks built via its US, German and Japanese subsidiaries.

With the 2025 acquisition of Vistos, the company's scope has broadened into lower-class devices such as fetal, neonatal and patient-monitoring equipment, positioning CU Medical to move from an emergency-device specialist toward a broader diagnostic and monitoring device supplier.

The company has said its Japan subsidiary secured a roughly 10,000-unit AED supply contract with Ramico, extending four straight years of order growth.

In Europe, the German subsidiary continues expanding public-access channels such as major UK supermarket chains, and the company recently unveiled a plan to link its AED remote-management solution with mobility services, seeking new channels to broaden emergency-care accessibility.

Having completed the change of largest shareholder at Vistos in January 2026, the company is integrating research labs and manufacturing/quality-control systems, and in February jointly exhibited with Vistos at WHX Dubai 2026, one of the Middle East's largest medical device trade shows, marking the first official display of post-acquisition synergy.

On the financing side, the company decided in July to redeem and cancel 2 billion won of the 7 billion won convertible bond issued in March 2026 ahead of maturity, partially reducing potential dilution risk.

Management has stated its intention to strengthen mid- to long-term growth by expanding global operations, including its German and Japanese subsidiaries.

Nonetheless, the timing of sequential certification for new Vistos products, the handling of the remaining convertible bond balance, and when integration synergies will show up in revenue remain variables that require continued confirmation through future disclosures.